

Late Gadolinium Enhancement in Cardiac MRI: Diagnostic and Prognostic Implications.

Samin Sharma*

Director, Interventional Cardiology, Mount Sinai, New York, USA

*Correspondence to: Samin Sharma, Director, Interventional Cardiology, Mount Sinai, New York, USA. Email: samin.sharma@mountsinai.org

Received: 27-May-2025, Manuscript No. AACCR-25-169793; Editor assigned: 01-Jun-2025, PreQC No. AACCR-25-169793 (PQ); Reviewed: 15-Jun-2025, QC No. AACCR-25-169793; Revised: 22-Jun-2025, Manuscript No. AACCR-25-169793 (R); Published: 29-Jun-2025, DOI:10.35841/AATCC-8.1.181

Introduction

Late Gadolinium Enhancement (LGE) has emerged as a powerful tool in the realm of cardiac magnetic resonance imaging (CMR), transforming the way cardiologists understand, diagnose, and monitor various myocardial pathologies. Its inception marked a significant advancement in non-invasive imaging technology, allowing clinicians to visualize myocardial scarring and fibrosis with exceptional precision. Unlike earlier modalities that relied on indirect markers of myocardial injury, LGE provides a direct and spatially resolved depiction of myocardial tissue characteristics, offering critical insights that influence clinical decision-making. The principle of LGE hinges on the differential washout kinetics of gadolinium-based contrast agents in healthy versus damaged myocardium. Gadolinium, an extracellular contrast agent, distributes into the interstitial space and is rapidly cleared from healthy myocardial tissue. However, in areas of myocardial injury, particularly those with expanded extracellular volume due to fibrosis or necrosis, gadolinium is retained for a longer period. This delayed washout forms the basis of the "late" enhancement observed on CMR images, typically 10-20 minutes post-contrast administration. The enhanced regions appear hyperintense on inversion recovery sequences, delineating the location and extent of myocardial damage.

LGE has become a standard technique in the evaluation of ischemic heart disease, where it plays a vital role in identifying myocardial infarction and assessing myocardial viability. The pattern of enhancement—typically subendocardial or transmural in a coronary artery distribution—correlates with the area of infarction. Moreover, the transmural extent of LGE is predictive of

functional recovery following revascularization; regions with less than 50% transmural involvement are more likely to regain contractile function post-intervention. Thus, LGE not only confirms the presence of myocardial infarction but also provides prognostic information that guides therapeutic strategies. Beyond ischemic cardiomyopathies, LGE has found substantial utility in non-ischemic cardiomyopathies, including hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), myocarditis, cardiac amyloidosis, and sarcoidosis. In HCM, for instance, LGE typically localizes to areas of hypertrophy and often appears as patchy mid-wall or subepicardial enhancement. The presence and extent of LGE in HCM patients are associated with increased risk of sudden cardiac death and adverse cardiac events, making it a critical tool in risk stratification and in decisions regarding implantable cardioverter-defibrillator (ICD) placement. In DCM, mid-wall fibrosis identified by LGE has similarly been linked to increased mortality and arrhythmic risk, independent of left ventricular ejection fraction.

In myocarditis, LGE provides diagnostic clarity through characteristic patterns of enhancement. Unlike ischemic injury, LGE in myocarditis often spares the subendocardium and manifests as patchy mid-wall or subepicardial enhancement, particularly in the lateral free wall of the left ventricle. The ability to non-invasively detect inflammation and necrosis makes LGE an essential component of the Lake Louise Criteria for diagnosing myocarditis via CMR. Infiltrative cardiomyopathies, such as cardiac amyloidosis and sarcoidosis, demonstrate unique LGE patterns—global subendocardial or transmural enhancement in amyloidosis and patchy nodular involvement in sarcoidosis—which aid in differential diagnosis and in monitoring disease progression or

therapeutic response. LGE also plays an instrumental role in the evaluation of arrhythmogenic substrates. Scar tissue identified through LGE correlates with sites of arrhythmia origin, and mapping these regions enhances the effectiveness of catheter ablation procedures. In patients with ventricular tachycardia, particularly those with structural heart disease, LGE facilitates the identification of arrhythmogenic foci, thereby improving procedural outcomes and reducing recurrence rates.

The quantitative assessment of LGE is another emerging area of clinical interest. Advances in imaging software now allow for volumetric measurement of scar burden, offering an objective metric that can be used in research and clinical follow-up. Quantitative LGE has been associated with outcomes in multiple studies, reinforcing its role not just as a qualitative marker but as a measurable biomarker of myocardial health. Despite its many advantages, LGE has some limitations. Gadolinium-based contrast agents carry a risk of nephrogenic systemic fibrosis in patients with severe renal dysfunction, which necessitates careful patient selection. Additionally, the sensitivity of LGE in detecting diffuse fibrosis is limited, as this technique is more adept at identifying focal scar. Newer techniques such as T1 mapping and extracellular volume (ECV) quantification are being developed to complement LGE by detecting diffuse interstitial changes with higher sensitivity.

From a technical perspective, LGE imaging requires optimal timing, appropriate inversion time selection, and meticulous planning to suppress the signal from healthy myocardium and accentuate the scar tissue. Artifacts arising from poor breath-holding, arrhythmias, or suboptimal contrast timing can impair image quality and diagnostic accuracy. Nevertheless, with standardized protocols and experienced technologists, these challenges can be effectively mitigated. The growing body of literature supporting LGE continues to validate its prognostic utility across a spectrum of cardiac diseases. Meta-analyses have shown that the presence of LGE is associated with increased all-cause mortality, cardiovascular mortality, and heart failure hospitalizations. As such, the incorporation of LGE findings into clinical practice guidelines is steadily increasing, cementing its role as a cornerstone of modern cardiac imaging.

Conclusion

Late Gadolinium Enhancement (LGE) has revolutionized cardiac magnetic resonance imaging by providing detailed, high-resolution visualization of myocardial fibrosis and scarring. Its diagnostic and prognostic capabilities extend across ischemic and non-ischemic cardiomyopathies, infiltrative diseases, inflammatory conditions, and arrhythmogenic substrates. While limitations exist, ongoing advancements in imaging techniques, contrast agent safety, and quantitative analysis continue to enhance its utility. As a result, LGE remains an indispensable tool in the modern cardiologist's armamentarium, shaping patient care through improved risk stratification, informed therapeutic decisions, and deeper understanding of myocardial pathology.

References

1. Alves, R., Ribeiro, J., & Ferreira, J. (2020). Effectiveness of chlorhexidine mouthrinse in preventing postoperative infections in oral surgery: A systematic review. *Journal of Oral and Maxillofacial Surgery*, 78(7), 1125–1134.
2. Coulthard, P., Esposito, M., Worthington, H. V., & van der Elst, M. (2014). Preoperative chlorhexidine mouth rinse for the prevention of postoperative infections: A Cochrane systematic review. *Cochrane Database of Systematic Reviews*, 2014(3), CD012705.
3. Herrero-Climent, M., Falcao, A., & Ríos-Santos, J. V. (2019). Efficacy of preoperative antiseptic mouth rinses in oral implantology: A randomized controlled trial. *Clinical Oral Implants Research*, 30(9), 837–845.
4. Koyuncu, B. O., & Gunbay, S. (2021). Antiseptic mouth rinses in oral surgery: Review of current evidence. *International Journal of Oral and Maxillofacial Surgery*, 50(4), 523–531.
5. Yaghoubian, A., Iqbal, S., & Kim, P. (2018). Reduction of oral microbial load with preoperative chlorhexidine rinse in third molar surgery: A clinical trial. *British Journal of Oral and Maxillofacial Surgery*, 56(5), 404–409.